Esperion Therapeutics
Update in progressESPR (NGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Esperion Therapeutics is a biopharmaceutical company focused on lowering LDL-C in the United States. It markets NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid with ezetimibe), once-daily oral non-statin medicines for adults with primary hyperlipidemia or heterozygous familial hypercholesterolemia who need additional LDL-C reduction. It also develops NILEMDO (ACL inhibitor) and NUSTENDI. Headquartered in Ann Arbor, Michigan, it collaborates with Daiichi Sankyo and Otsuka.
Company score
- Sentiment
- 0.21
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.04
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.01
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.10
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!